Abstract
Purpose
Serum levels of angiogenic cytokines decrease after radiotherapy in patients with cancer, and this may be relevant for treatment response and progression-free survival. Herein, we set out to determine whether circulating fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and platelet-derived growth factor-β (PDGF-β) decrease after radiotherapy in patients with non-Hodgkin lymphomas (NHLs) and if so, whether their decrease correlates with age, tumour histotype and stage, and radiation dose.
Material and methods
The serum levels of FGF-2, VEGF, HGF and PDGF-β were evaluated before and after radiotherapy by an enzyme-linked immunosorbent assay (ELISA). These levels were correlated both reciprocally and with age, histotype, stage and radiation dose.
Results
After radiotherapy, FGF-2, VEGF and PDGF-β, but not HGF, significantly decreased in relation to the radiation dose and response. No correlation was established between cytokine levels, except for VEGF and PDGF-β, which decreased in parallel. Haemoglobin levels did not decrease after radiotherapy, while FGF-2, VEGF, HGF and PDGF-β levels did not correlate with age, NHL stage and histotype.
Conclusions
Soluble FGF-2, VEGF and PDGF-β levels decline after radiotherapy in NHLs, and may have predictive significance for response to treatment and recurrence.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Folkman J (2001) Angiogenesis-dependent diseases. Semin Oncol 28:536–542
Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395
Carmeliet P, Moons L, Luttun A et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575–583
Ribatti D, Vacca A, Nico B et al (2001) The role of mast cells in tumour angiogenesis. Br J Haematol 115:514–521
Yu JL, Rak JW (2003) Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 5:83–88
Singh S, Sadanandam A, Singh RK (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26:453–467
Papetti H, Herman IM (2002) Mechanisms of normal and tumorderived angiogenesis. Am J Physiol Cell Physiol 282:C947–970
Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207–1225
Molica S, Vacca A, Ribatti D et al (2002) Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100:3344–3351
Ferrara N, Alitalo K (1999) Clinical Applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364
Bachtiary B, Selzer E, Knocke TH et al (2002) Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett 179:197–203
Dietz A, Rudat V, Conradt C et al (2000) Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 22:666–673
Chala E, Manes C, Iliades H et al (2006) Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones 5:137–146
Glenjen N, Mosevoll KA, Oystein B (2002) Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer 101:86–94
Urba ska-Rys H, Wierzbowska A, Robak T (2003) Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw 14:40–51
Ria R, Portaluri M, Russo F et al (2004) Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy. Cancer Lett 216:103–107
Barr MP, Bouchier-Hayes DJ, Harmey JJ (2008) Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol 32:41–48
Shi W, Teschendorf C, Muzyczka N et al (2003) Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 66:1–9
Rich JN (2007) Cancer stem cells in radiation resistance. Cancer Res 67:8980–8984
Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033–4042
Giannopoulou E, Katsoris P, Hatziapostolou M et al (2001) Xrays modulate extracellular matrix in vivo. Int J Cancer 94:690–698
Harada H, Kizaka-Kondoh S, Li G et al (2001) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26:7508–7516
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ria, R., Cirulli, T., Giannini, T. et al. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med 8, 141–145 (2008). https://doi.org/10.1007/s10238-008-0170-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-008-0170-2